NNC9204-0043

NNC9204-0043 is a long-acting glucagon receptor agonist developed by Novo Nordisk. It is primarily investigated for its metabolic effects in the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). As a glucagon receptor agonist, it promotes hepatic lipid metabolism, leading to a reduction in hepatic triglycerides and an increase in hepatic glycogen content. In preclinical models, it has been shown to enhance weight loss and improve liver health, particularly when used in combination with GLP-1 receptor agonists, by addressing hepatic steatosis through mechanisms independent of weight loss alone.

Other names

long-acting stable glucagon analog